Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-5100 miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0042H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Serum, Plasma-EDTA, Whole blood, Tissue, PBMC, Cultural lysates (HEK, HeLa)

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 3.8%

Inter-assay (Run-to-Run)

n = 5,
CV = 7.5%

Spiking Recovery

97.4%

Dilution Linearity

101.6%

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-5100 isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-5100 contributes to human carcinogenesis in various cancers, including glioblastoma, hepatocellular carcinoma (HCC), lung cancer and oral squamous cell carcinoma (OSCC). It was observed that miR-5100 was overexpressed in a subset of lung cancer tissues. miR-5100 overexpression increases the cisplatin resistance of the lung cancer stem cells (LCSCs) through the mitochondrial apoptosis pathway. The relative level of miR-5100 expression in non-small-cell lung cancer (NSCLC) tissues was significantly upregulated, compared with that in corresponding noncancerous tissues. NSCLC patients with higher miR-5100 expression had significantly poorer overall survival and progression-free survival. Overexpression of miR-5100 also inhibited colony formation, cell migration and invasion of pancreatic cancer cells.

miR-5100 plays an important role in the idiopathic pulmonary fibrosis (IPF). The study indicated that miR-5100 promotes the proliferation and metastasis of lung epithelial cells.

The expression levels of let-7f-5p, miR-5100 and miR-25-3p were significantly associated with the incidence rate of childhood acute lymphocytic leukemia (cALL), and these miRNAs might serve as promising biomarkers for cALL.

It was also shown, that miR-5100 negatively regulates Tob2, which acts as a negative regulator of osteogenesis. The important bone-related transcription factor osterix, which can be degraded by binding to Tob2, was influenced by miR-5100 during osteoblast differentiation.

The expression of miR-371b-5p and miR-5100 was increased significantly in the serum of systemic lupus erythematosus (SLE), compared with healthy controls and rheumatoid arthritis (RA) group. It was also higher in active SLE than in inactive SLE. The association was found between the expression levels of miR-371b-5p and miR-5100 and clinical parameters of SLE.

Summary References (11)

References to miR-5100

  • Dong L, Li Y, Han C, Wang X, She L, Zhang H. miRNA microarray reveals specificexpression in the peripheral blood of glioblastoma patients. Int J Oncol. 2014Aug;45(2):746-56. doi: 10.3892/ijo.2014.2459. Epub 2014 May 22. PubMed PMID:24858071. See more on PubMed
  • Huang H, Jiang Y, Wang Y, Chen T, Yang L, He H, Lin Z, Liu T, Yang T, Kamp DW,Wu B, Liu G. miR-5100 promotes tumor growth in lung cancer by targeting Rab6.Cancer Lett. 2015 Jun 28;362(1):15-24. doi: 10.1016/j.canlet.2015.03.004. Epub2015 Mar 6. PubMed PMID: 25754817. See more on PubMed
  • Chijiiwa Y, Moriyama T, Ohuchida K, Nabae T, Ohtsuka T, Miyasaka Y, Fujita H, Maeyama R, Manabe T, Abe A, Mizuuchi Y, Oda Y, Mizumoto K, Nakamura M.Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL. Int J Oncol. 2016 Apr;48(4):1688-700. doi:10.3892/ijo.2016.3389. Epub 2016 Feb 12. PubMed PMID: 26892887. See more on PubMed
  • Li CY, Wang YH, Lin ZY, Yang LW, Gao SL, Liu T, Zou BA, Pan ZC, Song ZQ, LiuG. MiR-5100 targets TOB2 to drive epithelial-mesenchymal transition associatedwith activating smad2/3 in lung epithelial cells. Am J Transl Res. 2017 Oct15;9(10):4694-4706. eCollection 2017. PubMed PMID: 29118928; PubMed CentralPMCID: PMC5666075. See more on PubMed
  • Shi J, Bao X, Liu Z, Zhang Z, Chen W, Xu Q. Serum miR-626 and miR-5100 arePromising Prognosis Predictors for Oral Squamous Cell Carcinoma. Theranostics.2019 Jan 25;9(4):920-931. doi: 10.7150/thno.30339. eCollection 2019. PubMed PMID:30867806; PubMed Central PMCID: PMC6401397. See more on PubMed
  • Sun X, Wang M, Liu H, Wang J. MicroRNA-423 enhances the invasiveness ofhepatocellular carcinoma via regulation of BRMS1. Am J Transl Res. 2017 Dec15;9(12):5576-5584. eCollection 2017. PubMed PMID: 29312509; PubMed CentralPMCID: PMC5752907. See more on PubMed
  • Wang H, Cui Y, Luan J, Zhou X, Li C, Li H, Shi L, Han J. MiR-5100 promotesosteogenic differentiation by targeting Tob2. J Bone Miner Metab. 2017Nov;35(6):608-615. doi: 10.1007/s00774-016-0799-y. Epub 2016 Nov 21. PubMed PMID:27873073. See more on PubMed
  • Wang T, Liu X, Tian Q, Liang T, Chang P. Increasing expression of miR-5100 in non-small-cell lung cancer and correlation with prognosis. Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3592-3597. PubMed PMID: 28925485. See more on PubMed
  • Yang L, Lin Z, Wang Y, Gao S, Li Q, Li C, Xu W, Chen J, Liu T, Song Z, Liu G. MiR-5100 increases the cisplatin resistance of the lung cancer stem cells byinhibiting the Rab6. Mol Carcinog. 2018 Mar;57(3):419-428. doi: 10.1002/mc.22765.Epub 2017 Dec 1. PubMed PMID: 29144562. See more on PubMed
  • Yuan DM, Wu SY, Huang SL, Jiang WC, Ke YB. [Association between expression of plasma miRNA and the risk of childhood acute lymphocytic leukemia]. Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Sep 10;38(9):1252-1258. doi:10.3760/cma.j.issn.0254-6450.2017.09.022. Chinese. PubMed PMID: 28910942. See more on PubMed
  • Zeng L, Wu JL, Liu LM, Jiang JQ, Wu HJ, Zhao M, Lu QJ. Serum miRNA-371b-5p andmiRNA-5100 act as biomarkers for systemic lupus erythematosus. Clin Immunol. 2018Nov;196:103-109. doi: 10.1016/j.clim.2018.10.004. Epub 2018 Oct 7. PubMed PMID:30304699. See more on PubMed
Related Products Docs